Cognition Disorders  >>  PF-02545920  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PF-02545920 / Pfizer
NCT01806896: Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease

Completed
2
37
Europe
PF-02545920, Placebo
Pfizer
Huntington's Disease
01/15
01/15
NCT02197130 / 2014-001291-56: Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease

Completed
2
272
US, Canada, Europe
PF-02545920, Placebo
Pfizer
Huntington's Disease
09/16
10/16
NCT02342548 / 2014-004900-31: Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

Terminated
2
188
US, Canada, Europe
20 mg BID of PF-02545920
Pfizer
Huntington's Disease
02/17
02/17

Download Options